Executive Summary: The Clinical Impact of GLP-1 Receptor Agonists on Metabolic Disease and Weight Management
Executive Summary GLP-1 (Glucagon-like peptide-1) receptor agonists represent a paradigm shift in the management of type 2 diabetes and obesity. Originally developed as incretin mimetics to improve glycemic control, their significant effects on weight reduction and cardiovascular protection have established them as a cornerstone of metabolic medicine. This class of therapeutics, including agents like semaglutide…